Total Payments
$343,223
2024 Payments
$40,003
Companies
31
Transactions
382
Medicare Patients
1,627
Medicare Billing
$266,321
Payment Breakdown by Category
Consulting$148,523 (43.3%)
Other$144,955 (42.2%)
Travel$34,788 (10.1%)
Food & Beverage$13,011 (3.8%)
Research$1,751 (0.5%)
Education$195.91 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $148,523 | 65 | 43.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,755 | 45 | 40.4% |
| Travel and Lodging | $34,788 | 106 | 10.1% |
| Food and Beverage | $13,011 | 150 | 3.8% |
| Honoraria | $6,200 | 2 | 1.8% |
| Unspecified | $1,751 | 4 | 0.5% |
| Education | $195.91 | 10 | 0.1% |
Payments by Type
General
$341,472
378 transactions
Research
$1,751
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $85,992 | 112 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $72,280 | 51 | $0 (2024) |
| GlaxoSmithKline, LLC. | $47,873 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $46,841 | 59 | $0 (2024) |
| Seagen Inc. | $16,506 | 14 | $0 (2023) |
| Stryker Corporation | $12,585 | 13 | $0 (2019) |
| Novocure Inc. | $10,755 | 7 | $0 (2023) |
| Eisai Inc. | $8,954 | 12 | $0 (2024) |
| Dova Pharmaceuticals | $7,292 | 7 | $0 (2019) |
| Incyte Corporation | $6,908 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,003 | 45 | GlaxoSmithKline, LLC. ($11,512) |
| 2023 | $22,403 | 19 | GlaxoSmithKline, LLC. ($6,750) |
| 2022 | $22,717 | 31 | Novocure Inc. ($5,950) |
| 2021 | $39,045 | 29 | GlaxoSmithKline, LLC. ($19,582) |
| 2020 | $7,079 | 7 | GlaxoSmithKline, LLC. ($6,113) |
| 2019 | $106,425 | 98 | AstraZeneca Pharmaceuticals LP ($60,378) |
| 2018 | $66,397 | 100 | TESARO, Inc. ($33,235) |
| 2017 | $39,155 | 53 | TESARO, Inc. ($36,966) |
All Payment Transactions
382 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $122.28 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $57.49 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $344.25 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $326.57 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: VACCINES | ||||||
| 10/08/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 09/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $69.54 | General |
| 09/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $13.39 | General |
| 09/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $6.37 | General |
| 09/14/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $28.05 | General |
| 09/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $120.28 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Endocrinology | ||||||
| 09/12/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $456.97 | General |
| Category: Endocrinology | ||||||
| 09/12/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $67.83 | General |
| Category: Endocrinology | ||||||
| 09/12/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $43.07 | General |
| Category: Endocrinology | ||||||
| 07/23/2024 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Endocrinology | ||||||
| 07/18/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Oncology | ||||||
| 07/16/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 07/02/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $4,019.51 | General |
| 06/05/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $460.98 | 2 |
| SGO 2018 | COVIDIEN LP | $340.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 405 | 645 | $280,840 | $67,668 |
| 2022 | 15 | 373 | 2,564 | $572,150 | $65,049 |
| 2021 | 12 | 405 | 654 | $211,625 | $63,813 |
| 2020 | 19 | 444 | 8,877 | $688,199 | $69,790 |
Total Patients
1,627
Total Services
12,740
Medicare Billing
$266,321
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 196 | $55,860 | $18,287 | 32.7% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 16 | 16 | $64,650 | $11,618 | 18.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 103 | 129 | $25,155 | $7,921 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 46 | $17,080 | $5,988 | 35.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 56 | $35,630 | $5,534 | 15.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $15,880 | $4,589 | 28.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 50 | $15,000 | $3,139 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 19 | $10,370 | $2,478 | 23.9% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 12 | 12 | $12,625 | $1,843 | 14.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,785 | $1,740 | 30.1% |
| 56820 | Exam of external female genitals using an endoscope | Office | 2023 | 14 | 19 | $9,635 | $1,601 | 16.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 17 | $5,610 | $1,511 | 26.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 36 | $7,560 | $1,419 | 18.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 147 | $41,895 | $12,958 | 30.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 89 | $32,040 | $12,358 | 38.6% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 14 | 14 | $56,980 | $9,962 | 17.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 15 | 66 | $40,920 | $7,024 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $14,935 | $4,566 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 67 | 85 | $16,575 | $4,518 | 27.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $9,430 | $2,990 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 27 | $8,910 | $2,193 | 24.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 37 | $11,100 | $2,095 | 18.9% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 11 | 11 | $9,900 | $1,610 | 16.3% |
| 56820 | Exam of external female genitals using an endoscope | Office | 2022 | 12 | 18 | $8,805 | $1,577 | 17.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 12 | 65 | $14,080 | $1,525 | 10.8% |
About Dr. Premal Thaker, MD
Dr. Premal Thaker, MD is a Gynecologic Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891739173.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Premal Thaker, MD has received a total of $343,223 in payments from pharmaceutical and medical device companies, with $40,003 received in 2024. These payments were reported across 382 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($148,523).
As a Medicare-enrolled provider, Thaker has provided services to 1,627 Medicare beneficiaries, totaling 12,740 services with total Medicare billing of $266,321. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Saint Louis, MO
- Active Since 06/16/2006
- Last Updated 04/17/2025
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1891739173
Products in Payments
- ZEJULA (Drug) $103,855
- LYNPARZA (Drug) $65,979
- KEYTRUDA (Biological) $34,054
- SPY TECHNOLOGY (Device) $10,050
- Lenvima (Drug) $8,888
- TIVDAK (Biological) $7,724
- Doptelet (Drug) $7,292
- Korlym (Drug) $6,612
- JEMPERLI (Biological) $5,545
- Rubraca (Drug) $2,880
- Optune (Device) $2,400
- FYARRO (Drug) $2,250
- KISQALI (Drug) $2,167
- Avastin (Biological) $1,745
- Amtagvi (Drug) $1,400
- NEW PRODUCT DEVELOPMENT (Device) $1,390
- 1588 HD 3 CHIP CAMERA (Device) $1,046
- Oncology (Device) $805.29
- LigaSure (Device) $540.00
- Sonicision (Device) $525.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Saint Louis
Dr. Matthew Powell, Md, MD
Gynecologic Oncology — Payments: $371,500
Gynecologic Oncology $371,500
Dr. David Mutch, Md, MD
Gynecologic Oncology — Payments: $89,524
Gynecologic Oncology $89,524
Dr. Carolyn Mccourt, Md, MD
Gynecologic Oncology — Payments: $34,327
Gynecologic Oncology $34,327
Dan-Arin Silasi, Md, MD
Gynecologic Oncology — Payments: $27,564
Gynecologic Oncology $27,564
Dr. Dineo Khabele, Md, MD
Gynecologic Oncology — Payments: $21,978
Gynecologic Oncology $21,978
Shannon Grabosch, M.d, M.D
Gynecologic Oncology — Payments: $10,087
Gynecologic Oncology $10,087